MT2A might be a chemosensitive indicator in gastric cancer (GC) [94], and another study found that MT2A might play a role in suppressing tumor activity through inhibiting NF-κB and might be a prognostic biomarker and potential target for individual therapy of GC [95] (Table 1). This evidence concerns the gene NFKB1 and gastric cancer.